Henry Gómez

25.9k total citations · 3 hit papers
205 papers, 8.3k citations indexed

About

Henry Gómez is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Henry Gómez has authored 205 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Oncology, 73 papers in Cancer Research and 70 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Henry Gómez's work include Cancer Treatment and Pharmacology (62 papers), Breast Cancer Treatment Studies (60 papers) and HER2/EGFR in Cancer Research (52 papers). Henry Gómez is often cited by papers focused on Cancer Treatment and Pharmacology (62 papers), Breast Cancer Treatment Studies (60 papers) and HER2/EGFR in Cancer Research (52 papers). Henry Gómez collaborates with scholars based in Peru, United States and Spain. Henry Gómez's co-authors include Justin M. Balko, Carlos L. Arteaga, Cristina Oliva, Xavier Pivot, Carlos A. Castañeda, Michael F. Press, Tatiana Vidaurre, H. Cortés-Funes, John Pippen and Melinda E. Sanders and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Henry Gómez

199 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

2009 766 citations Stephen Johnston, Xavier Pivot et al. Journal of Clinical Oncology profile →
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

2006 553 citations Kenneth R. Hess, W. Fraser Symmans et al. Journal of Clinical Oncology profile →
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

2017 479 citations Justin M. Balko, Luis J. Schwarz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henry Gómez Peru	46	5.3k	2.6k	2.6k	1.8k	801	205	8.3k
Philippe L. Bédard Canada	50	4.6k 0.9×	2.9k 1.1×	3.2k 1.2×	2.3k 1.3×	807 1.0×	347	9.7k
Fabio Puglisi Italy	43	4.8k 0.9×	2.5k 0.9×	2.3k 0.9×	2.4k 1.3×	971 1.2×	359	8.3k
Nuhad K. Ibrahim United States	42	6.3k 1.2×	3.9k 1.5×	2.8k 1.1×	1.8k 1.0×	1.1k 1.4×	145	10.0k
Henri Roché France	44	6.4k 1.2×	3.3k 1.3×	2.1k 0.8×	1.8k 1.0×	506 0.6×	213	9.0k
William T. Barry United States	47	4.3k 0.8×	2.4k 0.9×	2.1k 0.8×	1.6k 0.9×	807 1.0×	191	8.4k
Rebecca Dent Singapore	44	6.5k 1.2×	4.1k 1.5×	3.0k 1.2×	2.4k 1.3×	844 1.1×	186	10.2k
Carey K. Anders United States	45	5.4k 1.0×	2.6k 1.0×	2.0k 0.8×	2.8k 1.5×	672 0.8×	211	8.7k
Maura N. Dickler United States	47	6.4k 1.2×	2.8k 1.1×	3.4k 1.3×	3.3k 1.8×	952 1.2×	166	10.5k
Sheila E. Taube United States	21	4.5k 0.8×	3.5k 1.3×	3.2k 1.2×	1.8k 1.0×	893 1.1×	38	9.0k
George Somlo United States	51	6.1k 1.1×	3.8k 1.4×	4.7k 1.8×	1.8k 1.0×	957 1.2×	279	12.2k

Countries citing papers authored by Henry Gómez

Since Specialization

Citations

This map shows the geographic impact of Henry Gómez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Gómez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Gómez more than expected).

Fields of papers citing papers by Henry Gómez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry Gómez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Gómez. The network helps show where Henry Gómez may publish in the future.

Co-authorship network of co-authors of Henry Gómez

This figure shows the co-authorship network connecting the top 25 collaborators of Henry Gómez. A scholar is included among the top collaborators of Henry Gómez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Gómez. Henry Gómez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Valdiviezo, Natalia, Zaida Morante, Carlos A. Castañeda, et al.. (2024). Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2‐Positive Breast Cancer. International Journal of Breast Cancer. 2024(1). 9551710–9551710. 1 indexed citations

Gómez, Henry, et al.. (2024). Abstract PO1-28-03: Impact of the Oncotype DX® test over time and association with clinicopathological characteristics of Peruvian patients with early breast cancer: Experience in the last 15 years. Cancer Research. 84(9_Supplement). PO1–28.

Al‐Sukhun, Sana, Sarah Temin, Carlos H. Barrios, et al.. (2024). Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline. JCO Global Oncology. 10(10). e2300285–e2300285. 25 indexed citations

Araujo, Jhajaira M., Gabriel De la Cruz Ku, Melanie Cornejo, et al.. (2022). Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes. Cancers. 14(17). 4286–4286. 4 indexed citations

Castañeda, Carlos A., Miluska Castillo, Joselyn Sanchez, et al.. (2021). A biomarker study in Peruvian males with breast cancer. World Journal of Clinical Oncology. 12(10). 926–934. 1 indexed citations

Markopoulos, Christos, David M. Hyams, Henry Gómez, et al.. (2019). Multigene assays in early breast cancer: Insights from recent phase 3 studies. European Journal of Surgical Oncology. 46(4). 656–666. 20 indexed citations

Guevara, María L., Óscar Acosta, Joseph A. Pinto, et al.. (2017). Mutational analysis of BRCA 1 and BRCA 2 genes in Peruvian families with hereditary breast and ovarian cancer. Repositorio Académico USMP. 1 indexed citations

Hyams, David M., Eric R. Schuur, Enrique Bargalló‐Rocha, et al.. (2017). Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. Journal of Surgical Oncology. 115(6). 647–662. 10 indexed citations

Gómez, Henry, et al.. (2014). LIQUEN Parmotrema sancti angelii COMO BIOMONITOR DE LOS METALES PROVENIENTES DE LA MINA LOMA DE NIQUEL, ESTADO ARAGUA. 1 indexed citations

10.

Balko, Justin M., Luis J. Schwarz, Neil E. Bhola, et al.. (2013). Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer. Cancer Research. 73(20). 6346–6358. 122 indexed citations

11.

Dennison, Jennifer B., Jennifer R. Molina, Shreya Mitra, et al.. (2013). Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Cancer Research. 19(13). 3703–3713. 93 indexed citations

12.

Cristofanilli, Massimo, Stephen Johnston, Alexey Manikhas, et al.. (2012). A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Research and Treatment. 137(2). 471–482. 50 indexed citations

13.

Tabchy, Adel, Vicente Valero, Tatiana Vidaurre, et al.. (2010). Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. Clinical Cancer Research. 16(21). 5351–5361. 160 indexed citations

14.

Gómez, Henry, Joseph A. Pinto, Mivael Olivera, et al.. (2010). Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. The Breast. 20(1). 39–45. 7 indexed citations

15.

Vallejos, Carlos, Henry Gómez, Joseph A. Pinto, et al.. (2010). Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database. Clinical Breast Cancer. 10(4). 294–300. 112 indexed citations

16.

Gómez, Henry, Carlos A. Castañeda, Carlos E. Vigil, et al.. (2010). Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients. Hematology/Oncology and Stem Cell Therapy. 3(3). 109–115. 10 indexed citations

17.

Hortobágyi, Gabriel N., Henry Gómez, Rubi K. Li, et al.. (2010). Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Research and Treatment. 122(2). 409–418. 54 indexed citations

18.

Sherrill, Beth, Angelo Di Leo, Mayur M. Amonkar, et al.. (2010). Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Current Medical Research and Opinion. 26(4). 767–775. 12 indexed citations

19.

Scaltriti, Maurizio, Sarat Chandarlapaty, Ludmila Prudkin, et al.. (2010). Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research. 16(9). 2688–2695. 114 indexed citations

20.

Leo, Angelo Di, Henry Gómez, Zeba Aziz, et al.. (2008). Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. Journal of Clinical Oncology. 26(34). 5544–5552. 345 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact